Approved Wire coverage, newest first. Market moves and thesis evidence remain separate.
Novo Nordisk reported Q2 2026 adjusted operating profit of DKK 33,389 million and raised its full-year outlook. The guidance hike signals management sees continued strength in GLP-1 demand outpacing prior expectations, a key data point after a stretch of intensified competition from Eli Lilly and pricing pressure narratives.
Timken beat Q2 2026 estimates and raised full-year guidance as its ongoing business transformation shows early results. The company's FY2025 revenue was roughly flat at $4.6B, so the beat-and-raise narrative hinges on margin and execution improvement rather than top-line growth, raising the question of whether the market rewards the guide or waits for proof in the next print.
Spotify missed earnings by €0.15 per share and revenue also came in below estimates, snapping the company's recent run of beats. The miss raises questions about whether Spotify's premium pricing and margin-expansion story is decelerating just as investors had priced in continued outperformance.
Zebra Technologies posted record Q2 2026 results and raised its full-year outlook, citing AI-driven demand momentum. The beat-and-raise sets up a test of whether the stock's reaction can hold through the next quarter as investors assess durability of the AI-linked demand cycle.
Caterpillar shares jumped 9% after the company reported record quarterly revenue, with FY figures showing $67.6B in revenue (+4.3% YoY) and 13.1% net margin on $18.81 diluted EPS. The move suggests demand strength in construction, mining, and energy equipment is holding up better than feared, resetting the bar for how the market prices cyclical industrials into the back half of the year.
Palantir shares jumped after the company reported strong quarterly results, with broader futures also lifted by a Trump-driven market rally. The setup now shifts to whether Palantir's re-rated valuation can hold as investors look ahead to SpaceX-related catalysts and the next print.
Grainger shares fell after the company beat earnings but reported gross margin compression alongside news of its CFO's resignation.
Palantir posted second-quarter results with US sales climbing 23% and management forecasting greater demand from US commercial and government groups for its AI software. The company's FY2025 filings show revenue of $4.5B (+56.2% YoY), 82.4% gross margin, and $0.63 diluted EPS, underscoring the scale of its current growth trajectory.
Advanced Energy Industries beat EPS estimates by $0.54 and topped revenue expectations, with FY revenue running at $1.8B, up 21.4% YoY. The beat-and-raise setup on strong semi-cap and power-electronics demand sets up a test of whether the stock can hold gains or fades on guidance nuance.
The FAA has approved Boeing's 737 MAX-7 for production, removing a certification bottleneck that has weighed on Boeing's narrowbody delivery ramp, and shares jumped 5% on the news. This clears a path toward MAX-7 deliveries and adds a new certified variant to Boeing's production line at a time when the company is trying to scale output and improve cash generation.
Marriott's outlook fell short of expectations as ongoing Middle East conflicts continue to weigh on travel demand and RevPAR trends. The guidance cut raises questions about how long geopolitical disruption will pressure international bookings for the world's largest hotel operator.
Tyson Foods cut its profit forecast, citing tight US cattle supplies that are squeezing its beef segment margins. The cut signals persistent input cost pressure that may extend beyond this quarter given cattle herd rebuild cycles typically span years.
Amazon shares jumped 15% while Apple lost roughly $475 billion in market value in a sharp divergence in mega-cap earnings reactions. The moves suggest investors are rewarding Amazon's growth trajectory ($716.9B revenue, +12.4% YoY) while punishing Apple despite still-strong margins (46.9% gross, 26.9% net) on slower top-line growth (+6.4% YoY).
Apple shares slumped following Tim Cook's final earnings report as CEO, while Microsoft rallied in the same big-tech reporting week. The divergence sets up a pairs question on which mega-cap has stronger near-term earnings momentum heading into the next stretch of the cycle.
Novo Nordisk shares fell 10% after a cardiovascular drug trial disappointed, undercutting the company's push to diversify beyond Wegovy and Ozempic. The setup now tests whether investors treat this as a one-off pipeline miss or as evidence Novo's ex-obesity growth story is structurally weaker than priced.